MDGL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Madrigal Pharmaceuticals Inc (MDGL) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock has shown significant growth in revenue and hedge fund interest, the financial performance is weak with declining net income and EPS. The technical indicators suggest the stock is overbought, and analyst ratings are mixed, with some downgrades and reduced price targets. The options data indicates a bullish sentiment, but the lack of recent SwingMax or AI Stock Picker signals further supports a cautious approach. For a long-term investor, it's better to wait for a more favorable entry point or improved financial performance.
The stock is in a bullish trend with MACD positively expanding, bullish moving averages (SMA_5 > SMA_20 > SMA_200), and a current RSI of 85.355, indicating an overbought condition. Key resistance levels are R1: 552.402 and R2: 584.296, while support levels are S1: 449.149 and S2: 417.254.
Hedge fund buying has increased significantly by 176.46% over the last quarter. The regenerative medicine market is projected to grow substantially, which could benefit Madrigal Pharmaceuticals in the long term.
The stock is overbought based on RSI, and Wolfe Research recently downgraded the stock, citing valuation concerns and weak patent strength. Financial performance shows declining net income, EPS, and gross margin.
In Q4 2025, revenue increased significantly by 210.77% YoY to $321.08M. However, net income dropped to -$58.58M (-1.42% YoY), EPS decreased to -2.55 (-5.90% YoY), and gross margin declined to 92.39 (-4.43% YoY).
Mixed ratings from analysts. Barclays initiated coverage with an Overweight rating and a $964 price target, while Wolfe Research downgraded the stock to Peer Perform, citing valuation concerns. BofA has lowered its price target twice recently, reflecting cautious sentiment.
